Omnipaque Injection (Iohexol)

Iohexol, the active ingredient in Omnipaque Injection, is a non‑ionic contrast media presented as a sterile aqueous solution for intravenous use. It is employed in diagnostic imaging procedures to enhance the visibility of vascular structures and organs. GNH USA supplies Omnipaque Injection as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Omnipaque Injection as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Omnipaque Injection is a non‑ionic contrast agent used in radiographic procedures that require enhanced imaging of body structures.

- Angiography: Improves visualisation of blood vessels during cerebral, coronary and peripheral studies. - Computed Tomography (CT): Provides high‑contrast images of abdominal, thoracic and head scans. - Intravenous uro‑urography: Enhances delineation of the urinary tract during excretory phase imaging. - Myelography: Facilitates clear imaging of the spinal canal and nerve roots. - Endovascular interventions: Supports real‑time imaging guidance during minimally‑invasive therapeutic procedures.

Adverse reactions to Omnipaque Injection can range from mild to severe and should be monitored during and after administration.

Common Side Effects: - Warm sensation or flushing: Transient feeling of heat in the face or neck. - Nausea or vomiting: Mild gastrointestinal upset following injection. - Headache: Temporary headache that resolves without intervention. - Metallic taste: Brief metallic sensation in the mouth. - Mild urination urgency: Temporary increase in urinary frequency.

Serious or Rare Side Effects: - Anaphylactoid reaction: Rapid onset of hives, bronchospasm, or hypotension. - Renal impairment: Acute kidney injury, especially in patients with pre‑existing renal disease. - Severe hypotension: Sudden drop in blood pressure requiring medical management. - Cardiac arrhythmias: Irregular heart rhythms observed during or after injection. - Pulmonary edema: Fluid accumulation in the lungs presenting with breathlessness.

Before using Omnipaque Injection, clinicians should assess patient history and monitor for potential adverse events.

- Renal function assessment: Evaluate baseline creatinine and eGFR, especially in at‑risk patients. - Allergy history: Verify prior reactions to iodine‑based contrast or other contrast media. - Hydration status: Ensure adequate fluid intake before and after the procedure to support renal clearance. - Concomitant nephrotoxic drugs: Review and possibly suspend medications such as NSAIDs or aminoglycosides. - Thyroid function: Consider testing in patients with known thyroid disorders. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake the vial.

Omnipaque Injection may interact with other agents that affect renal function or cause hypersensitivity.

Major Interactions (Avoid): - Aminoglycoside antibiotics: Increased risk of nephrotoxicity when combined with iodinated contrast. - Loop diuretics: May exacerbate renal impairment and fluid‑electrolyte disturbances.

Moderate Interactions (Monitor Closely): - Metformin: Potential for lactic acidosis in patients with reduced renal clearance; withhold temporarily after contrast exposure. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): May heighten risk of contrast‑induced nephropathy. - ACE inhibitors/ARBs: Can affect renal haemodynamics; monitor kidney function closely.